]>Iron Chelation Therapy in Myelodysplastic Syndromes : Table 1
Table 1: Overview of the published guidelines for iron chelation therapy in MDS patients. RBC (red blood cell), IPSS (International Prognostic Scoring System).
GuidelinesItaly 2002UK 2003Nagasaki Consensus 2005Canada 2008Spain 2008Japan 2008MDS Foundation 2008Austria 2008Israel 2008NCCN 2009
Transfusion statusReceived ≥50 RBC unitsReceived ~25 RBC unitsTransfusion dependentTransfusion dependentTransfusion dependentReceived >40 Japanese unitsReceived 2 RBC units/month for ≥1 yearTransfusion dependentReceived 20–25 RBC units or more than 2 RBC units/month for 6 monthsReceived 20–30 RBC units to continue transfusions
Serum ferritin level(ng/mL)——>1000 –2000>1000>1000>1000>1000>2000>1000>2500
PatientsLife-expectancy >6 monthsLong-term survival likely (eg, pure sideroblastic anemia, del(5q))Low or Int-1 IPSS Refractory anemia (RA), RA with ringed sideroblasts (RARS), del(5q)Low or Int-1 IPSS, RA, RARS, del(5q) (Int-2 or High IPSS)IPSS Low or Int-1, Low risk (Spanish prognostic index)Life-expectancy >1 yearLife-expectancy >1 yearLife expectancy >2 yearsLife-expectancy >1 yearLow or Int-1 IPSS